Skip to main content
Menu

Posts tagged with "Cardiovascular Disease"

  • Aging and Lifespan

    Metformin and Exercise

    I’ve written about metformin quite a few times over the years on the blog, and for several reasons. It is (for starters) obviously a frontline drug for treatment of Type 2 diabetes, a condition that has unfortunately become more and more common in the world as the world puts on more and more weight. (Side… Read More
  • Cancer

    A Run of Contrary Results

    From the outside, medical progress looks a lot easier than it really is. Well, I realize that’s true of a lot of things, but it’s especially true in progress against disease, and that’s especially especially true (as I’ve said here before) when you’re talking about dietary influences and what can be learned from them.… Read More
  • Cardiovascular Disease

    Inhaled Nanoparticles – Good Ones, That Is

    Never give up on drug delivery ideas – that’s one of the big points I get out of this paper. The authors, part of a multi-center team from sites in Italy and Germany, have previously shown that calcium phosphate nanoparticles could be a good carrier for delicate cargo such as microRNAs. Such things tend to… Read More
  • Cardiovascular Disease

    AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking about anything to do with the response to levels of fuel like glucose or fatty acids and determination of their downstream fates, then AMPK is almost certainly crucial. Activating the enzyme se… Read More
  • Cardiovascular Disease

    Hold On, Merck’s CETP Inhibitor Actually Works?

    Well, maybe. I have to admit that my first reaction was disbelief. Merck has come out this morning with a statement that its long-running outcomes trial with anacetrapib, their cholesteryl ester transfer protein (CETP) inhibitor, had positive results. Specifically, they say that the trial. . . . . .met its primary endpoint, significantly reducing m… Read More
  • Cardiovascular Disease

    Two Diabetes Drug Mysteries

    Here are some data to file under “Drugs do things that we don’t expect”. The SGLT-2 inhibitors are a class of diabetes medications that work by inhibiting the sodium/glucose transporter 2 protein in the kidneys. That keeps glucose from being reabsorbed there; instead, more of it is removed in the urine, and that lowers circulating… Read More
  • Cardiovascular Disease

    Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you haven’t been doing this stuff long enough”. Well, it’s pretty hard to hold your breath across a full tox study, but you know what I mean. There are… Read More
  • Cardiovascular Disease

    Now This Is A Drug That Does Not Work

    I’ve already written about how Eli Lilly’s inhibitor of cholesteryl ester transfer protein (CETP) did not work in the clinic. Now that the data from their failed trial have been published in the NEJM, though, it’s worth taking a look at a few graphs (first pointed out to me on Twitter by Sek Kathiresan. Shown are… Read More
  • Cardiovascular Disease

    A Clinical Trial Torpedoed By Fraud and Incompetence

    Via @AndyBiotech on Twitter, here’s a story on some very troubling developments in offshore clinical trials. That Cardiobrief article is referring to this letter in NEJM, and the subject is the NIH’s trial of spironolactone in heart failure patients. The TOPCAT trial enrolled 3445 participants  in 6 countries (1151 in the US, 326 i… Read More
  • Cardiovascular Disease

    The Genomics Revolution Shows Up Late, But Shows Up

    Robert Plenge has an excellent overview of the PCSK9 story up on his site; I recommend it. His take may sound different from mine at first, but I think we’re actually in agreement on a lot of important points. I said that “PCSK9 is about as compelling a story as we’re likely to see in… Read More
123...